Item 1.02. Termination of a Material Definitive Agreement.

On October 1, 2021, Sarepta Therapeutics, Inc. ("Sarepta") notified Codiak BioSciences, Inc. (the "Company") that it was terminating early the two-year Research License and Option Agreement, effective June 17, 2020, between Sarepta and the Company (the "Agreement"). The notice was given pursuant to Section 11.2 of the Agreement, which provides that Sarepta could terminate the Agreement for any reason or no reason at any time upon 60 days' prior written notice to Codiak. The termination will be effective as of December 3, 2021.

As previously disclosed, the Agreement focused on the use of exosomes for non-viral delivery of AAV, gene-editing and RNA therapeutics to address five agreed targets associated with neuromuscular diseases. Pursuant to the Agreement, the Company received funding to conduct collaborative research and Sarepta had options to enter into exclusive, worldwide licenses for each of the agreed targets to develop, commercialize and manufacture therapeutic candidates developed using the Company's engEx Platform. Under the terms of the Agreement, the Company received up-front and non-refundable cash payments totaling $10.0 million, consisting of a $7.0 million up-front payment and a $3.0 million up-front research services prepayment.

Under the terms of the Agreement, the Company granted to Sarepta a non-exclusive, royalty-free, worldwide license, with a limited right to sublicense, to use certain intellectual property of the Company in the conduct of activities for which Sarepta was responsible under the Agreement. The Company also granted to Sarepta an option to obtain an exclusive, worldwide, sublicensable license to use certain intellectual property of the Company for the development, manufacturing and commercialization of exosome therapeutic candidates directed to one or more of the five agreed targets. As a result of the termination, each of the license and option granted to Sarepta shall terminate in its entirety, according to the terms of the Agreement, and the Company shall regain all rights previously granted to Sarepta.

A copy of the Agreement was filed as Exhibit 10.15 to the Company's Registration Statement on Form S-1, filed on September 9, 2020. The description of the Agreement contained in this Current Report on Form 8-K is qualified in its entirety by reference to the copy of the Agreement filed as Exhibit 10.15 to the Registration Statement on Form S-1, filed on September 9, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses